StockNews.com Initiates Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

Research analysts at StockNews.com began coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a note issued to investors on Saturday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Stock Performance

NASDAQ ADXS opened at $0.03 on Friday. The business has a fifty day moving average price of $0.04 and a 200 day moving average price of $0.18. Ayala Pharmaceuticals has a one year low of $0.00 and a one year high of $1.49. The company has a market cap of $1.16 million, a P/E ratio of 0.00 and a beta of 1.72.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.